All In Biotech

Drug Trial Radar · NCT02365493

Combination Antibiotic Therapy for Methicillin Resistant Staphylococcus Aureus Infection

CAMERA 2 - Combination Antibiotic Therapy for Methicillin Resistant Staphylococcus Aureus Infection - An Investigator-initiated, Multi-centre, Parallel Group, Open Labelled Randomised Controlled Trial

Last checked: Nov 19, 2026Latest source record: Dec 19, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedPivotal-lookingPhase 3. Randomized with 358 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

358

Actual

Start

Aug 26, 2015

Primary completion

Oct 24, 2018

Study completion Oct 24, 2018

Sponsor

Lead sponsor
Menzies School of Health ResearchAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Australasian Society for Infectious Diseases; Singapore Infectious Diseases Clinical Research Network; The University of Queensland; Australasian Kidney Trials Network
First posted
Feb 19, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The aim of this clinical trial is to determine whether a novel combination antibiotic treatment (vancomycin/daptomycin + beta-lactam) is superior to the standard antibiotic treatment (vancomycin/daptomycin) for hospitalised adults with Methicillin Resistant Staphylococcus aureus bacteraemia. The hypothesis is that the addition of beta-lactam antibiotics (these are antibiotics from the penicillin family) to the standard therapy will lead to more efficient bacterial killing and hence lead to faster clearance of bacteria from the blood stream and other areas of infection, thereby reducing the risk of the spread of infection and death. The study design is an investigator-initiated, multi-centre, open-label, randomised controlled trial. This will include 440 participants diagnosed with Methicillin Resistant Staphylococcus aureus bacteraemia recruited over a period of 4 years (July 2015 - June 2019) from within Infectious Diseases inpatient units across 21 hospital sites including 18 from within Australia and 3 located in Singapore. Participation will be voluntary and subject to informed consent. The participants will be randomised 1:1 to either the standard therapy group or combination therapy group. The combination therapy will include a treatment of intravenous beta-lactam for the first 7 days of treatment, in addition to the standard treatment (either vancomycin or daptomycin). The primary outcome measure will be complication-free survival 90 days post randomisation.

Conditions

  • Methicillin-Resistant Staphylococcus Aureus

Interventions

  • Beta-LactamDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Complication-free 90 day survivalTime frame: Time period from randomisation (day 1) to day 90

Locations

30 sites in 4 countries. Site status is shown where the registry gives one.

  • Blacktown Hospital

    Blacktown, New South Wales, Australia

  • Royal Prince Alfred Hospital

    Camperdown, New South Wales, Australia

  • Concord Repatriation General Hospital

    Concord, New South Wales, Australia

  • St Vincent's Hospital

    Darlinghurst, New South Wales, Australia

  • Nepean Hospital

    Kingswood, New South Wales, Australia

  • Liverpool Hospital

    Liverpool, New South Wales, Australia

  • John Hunter Hospital

    New Lambton Heights, New South Wales, Australia

  • Westmead Hospital

    Westmead, New South Wales, Australia

  • Wollongong Hospital

    Wollongong, New South Wales, Australia

  • Royal Darwin Hospital

    Darwin, Northern Territory, Australia

  • Cairns Hospital

    Cairns, Queensland, Australia

  • Royal Brisbane and Women's Hospital

    Herston, Queensland, Australia

  • Princess Alexandra Hospital

    Woolloongabba, Queensland, Australia

  • Royal Adelaide Hospital

    Adelaide, South Australia, Australia

  • Flinder's Medical Centre

    Bedford Park, South Australia, Australia

  • The Queen Elizabeth Hospital

    Woodville South, South Australia, Australia

  • Monash Medical Centre Clayton Campus

    Clayton, Victoria, Australia

  • Dandenong Hospital

    Dandenong, Victoria, Australia

  • Western Health - Footscray

    Footscray, Victoria, Australia

  • Austin Hospital

    Heidelberg, Victoria, Australia

  • Western Health - Sunshine Hospital

    Sunshine, Victoria, Australia

  • Western Health - Williamstown Hospital

    Williamstown, Victoria, Australia

  • Fiona Stanley Hospital

    Murdoch, Western Australia, Australia

  • Royal Perth Hospital

    Perth, Western Australia, Australia

  • Rambam Health Corporation

    Haifa, Israel

  • Beilinson Hospital

    Petah Tikva, Israel

  • Middlemore Hospital

    Otahuhu, Auckland, New Zealand

  • National University Hospital

    Kent Ridge, Singapore

  • Singapore General Hospital

    Outram Park, Singapore

  • Tan Tock Seng Hospital

    Novena, Tan Tock Seng, Singapore

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.